Lapatinib Ditosylate is an antineoplastic agent and tyrosine kinase inhibitor indicated for the treatment of certain advanced or metastatic breast cancers. By blocking specific protein kinases involved… Read more





Lapatinib Ditosylate is an antineoplastic agent and tyrosine kinase inhibitor indicated for the treatment of certain advanced or metastatic breast cancers. By blocking specific protein kinases involved in cell growth and signaling, it helps inhibit tumor progression. This category provides essential reference standards, including the active pharmaceutical ingredient, its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds. Pharmaceutical laboratories utilize these high-quality materials for critical analytical tasks, such as impurity profiling, method validation, and routine quality control testing. Access to accurate, fully characterized standards ensures that researchers and manufacturers can reliably monitor the purity and degradation pathways of Lapatinib Ditosylate, supporting the development and safety of therapeutic formulations throughout the drug lifecycle.